EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Investigation of the Relevance of CYP3A4 Inhibition on the Pharmacokinetics of the Novel P2X3 Antagonist Filapixant: Results of In Vitro Explorations and a Fixed-Sequence Clinical Trial with Itraconazole in Healthy Volunteers

Klaus Francke, Antje Rottmann, Stefan Klein, Joachim Höchel iD, Christian Friedrich iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262010177 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Klaus Francke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany. Hauptthemen laut MEDLINE: Itraconazole, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inhibitors, Purinergic P2X Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypersensitized P2X3 receptor signaling has been described to play a role in several disorders, including chronic cough. The goal of our in vitro and in vivo studies was to investigate the biotransformation and the influence of CYP3A4 inhibition on the pharmacokinetics of the selective P2X3 antagonist filapixant. Metabolic turnover of filapixant in human liver microsomes and hepatocytes was moderate to high, indicating a complex metabolic pattern with mainly oxidative biotransformation. In recombinant CYP enzymes, depletion of filapixant was observed mainly with CYP3A4 and, to a significantly lesser extent, with CYP1A1, 2D6, 2J2, and 3A5. Drug depletion of [3H]filapixant and metabolite formation in human liver microsomes was significantly inhibited in the presence of strong CYP3A4 inhibitors, whereas other CYP isoform–selective inhibitors showed no or very minor effects. Co-administration of multiple daily doses of 200 mg itraconazole with 80 mg filapixant in humans increased the AUC and Cmax of filapixant to 4.01 and 1.89-fold, respectively, indicating that filapixant is a moderately sensitive CYP3A4 substrate. Co-administration of itraconazole also prolonged the half-life of filapixant from 12.1 h to 22.8 h. Overall, changes in AUC, Cmax, and half-life indicate that both the bioavailability and elimination of filapixant were affected. Filapixant was well tolerated alone and in combination with itraconazole.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ItraconazoleCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsPurinergic P2X Receptor AntagonistsHumansMicrosomes, LiverMaleAdultHealthy VolunteersHepatocytesYoung AdultFemaleDrug Interactions

Stichwörter der Autor:innen

P2X3-anatgonistdrug–drug interactionfilapixantitraconazolepharmacokinetic

Substanzen

ItraconazoleCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsCYP3A4 protein, humanPurinergic P2X Receptor Antagonists

Autor:innen und Institutionen

  • Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
  • MHB-Medizinische Hochschule Brandenburg, 14770 Brandenburg, Germany.

ORCID-Profile: Joachim Höchel, Christian Friedrich

Zitieren

APA

Francke, K., Rottmann, A., Klein, S., Höchel, J., & Friedrich, C. (2025). Investigation of the Relevance of CYP3A4 Inhibition on the Pharmacokinetics of the Novel P2X3 Antagonist Filapixant: Results of In Vitro Explorations and a Fixed-Sequence Clinical Trial with Itraconazole in Healthy Volunteers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010177

Vancouver

Francke K, Rottmann A, Klein S, Höchel J, Friedrich C. Investigation of the Relevance of CYP3A4 Inhibition on the Pharmacokinetics of the Novel P2X3 Antagonist Filapixant: Results of In Vitro Explorations and a Fixed-Sequence Clinical Trial with Itraconazole in Healthy Volunteers. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010177

BibTeX
@article{Francke2025,
  author = {Francke, Klaus and Rottmann, Antje and Klein, Stefan and Höchel, Joachim and Friedrich, Christian},
  title = {Investigation of the Relevance of CYP3A4 Inhibition on the Pharmacokinetics of the Novel P2X3 Antagonist Filapixant: Results of In Vitro Explorations and a Fixed-Sequence Clinical Trial with Itraconazole in Healthy Volunteers},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262010177}
}
Kostenlos starten →